SkinBioTherapeutics PLC

SkinBioTherapeutics appoints soon-to-be CEO to the board

SkinBio said Stuart John Ashman’s appointment would allow him to gain an understanding of the business while incumbent CEO Dr Cath O’Neill would focus on the company’s scientific developments and ongoing commercial discussions

Board room table
Ashman's board appointment is effective immediately

SkinBioTherapeutics PLC (LON:SBTX) has appointed soon-to-be chief executive, Stuart John Ashman, to the board as an executive director.

Ashman, who was announced as the successor to incumbent CEO Dr Cath O'Neill at the end of March, previously served as the director of sales and marketing at FTSE 100-listed Smith & Nephew PLC (LON:SN.) in its wound care, casting and bandaging division.

READ: SkinBioTherapeutics names ex-Smith & Nephew sales boss as new CEO

SkinBio said Ashman’s appointment to the board would allow him to gain an understanding of the business while O’Neill would focus on the company’s scientific developments and ongoing commercial discussions.

"Stuart's appointment as a director adds further commercial capability to the board. He has a considerable network within the medtech and life science industries and he has the experience and drive to take us forward on the next stage of the company's development," said Martin Hunt, the company’s non-executive chairman.

READ: SkinBioTherapeutics chief "really pleased" with human trial data for new skin cream

O’Neill will likely be turning her attention to the group’s first human study for its SkinBiotix cream, with data last week showing the product had produced a statistically significant increase in skin hydration for the under 50s cohort and a small, but statistically significant decrease in transepidermal water loss at day 29 in the over 60s cohort.

At the time, O’Neill said there was “a lot of scope” for the company to further optimise the formulation of the cream to make it more suitable for different age groups.

In early trading on Thursday, SkinBio shares were down 1.4% at 17.7p.

-- Adds share price --

Quick facts: SkinBioTherapeutics PLC

Price: £0.16

Market: AIM
Market Cap: £20.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...



SkinBioTherapeutics' Cath O'Neill 'thrilled' with human study data for skin...

Dr Cath O’Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), speaks to Proactive's Andrew Scott after announcing the results from the company’s first human study of its SkinBiotix cream. The data has shown the product to be well tolerated and efficacious in certain age groups...

on 9/4/19

2 min read